To define the optimal laboratory reference intervals for platelet function test in patients with acute coronary syndrome (ACS) on dual-antiplatelet therapy (DAPT).
Material and methods
Four hundred twenty five patients with ACS were enrolled in the single center prospective cohort registry (CARDIO-CCH). Platelet function testing (PFT) was performed in all patients (Chrono-Log Corporation, USA). Thirty day major adverse cardiac events (MACE) were recorded and matched up with the results of PFT to calculate "therapeutic window".
Upper "therapeutic window" cut-off point associated with an acceptable risk of ischemic events was calculated at the level of 45%. It is recommended to use 30% PFT rate as a lower cut-off limit which was associated with an increased risk of hemorrhagic events. However, lower cut-off point needs further investigations.
Optimal "therapeutic window" for PFT in patients with ACS on DAPT is in the interval from 30% to 45%.
Acute coronary syndrome, platelet aggregation, thrombosis, bleedings, antiplatelet therapy.